This biotech stock is set to nearly quadruple on the back of its advanced gene therapy products, says Cantor Fitzgerald

[ad_1]

The rollout of several gene therapy products targeting extremely rare diseases could boost this stock 286%, according to Cantor Fitzgerald.

[ad_2]

Source link